Although biosimilars are usually cheaper than biologic brand-name drugs, a patient’s insurance plan can have a lot of sway in biosimilar drug prices, a recent study found.
Read the full post on Becker's Hospital Review - Healthcare News
Wrapped in employer insurance plans, biosimilars can be more expensive
